A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: randomized, placebo-controlled, double-blind clinical trial
Early research suggests it may be more effective than GHK-Cu for hair-specific applications, though the evidence base is smaller
FTC Crackdown on Telehealth Claims The FTC is taking action against telehealth firms using misleading prices, fake reviews, or deceptive weight loss claims, expanding oversight beyond medication to patient communications and marketing
Although lixisenatide is administered once a day, it is still considered a short-acting GLP-1RA [18]
Fasting lipid panels provide most accurate triglyceride measurements
By early 2026, FDA had publicly announced enforcement actions against multiple compounded GLP-1 telehealth platforms, and in April 2026 formally proposed removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list - with a public comment period running through June 2026